Increasingly transrectal ultrasound and biopsy is performed for the detection of prostate cancer. We have conducted a randomised trial to evaluate whether the addition of periprostatic local anaesthetic injection reduces the discomfort of the procedure. A total of 64 patients who attended a specialised prostate clinic and were being evaluated for an elevated prostate-specific antigen agreed to participate in the trial and were randomly allocated to two groups. The intervention group received 10 ml of 1% lignocaine in the periprostatic tissue prior to biopsy and the control group underwent a standard biopsy. All patients had a sextant biopsy under ultrasound guidance. After the procedure, they were asked to determine the severity of the pain on a scale of 0-10 and the whether the quality of the pain was mild, moderate or severe. The responses were distributed normally. The groups were compared using Student's t-test. Pain severity showed no significant difference between the two groups (P ¼ 0.14). There was a trend towards a statistical difference (P ¼ 0.07) on the qualitative pain scale. In conclusion, no significant difference in overall discomfort in men having sextant biopsies was detected between the two groups, suggesting that the administration of local anaesthetic may not be as valuable as early reports have suggested.
Introduction
Prostate cancer is increasingly recognised as a major public health care problem with 17 210 new cases registered in England and Wales in 1993, and 8570 deaths. 1 Screening for prostate cancer remains controversial, any man considering a prostate-specific antigen (PSA) test should be given detailed information to enable him to make an informed choice about whether to proceed with a test or not. To confirm cancer, the patient must undergo a transrectal ultrasound and biopsy. This procedure is usually performed on an outpatient basis. Patients are informed that the biopsy may be uncomfortable. Great interest was generated when a report published that the use of local anaesthesia prior to ultrasound guided prostate biopsy dramatically decreased the discomfort of the procedure. The authors were so enthusiastic that they urged all urologists to rapidly change their practice patterns and adopt the technique immediately. 2 We have prospectively evaluated the role of periprostatic nerve block to determine if it reduced the overall discomfort of the procedure.
Patients and methods
We prospectively evaluated 64 men who attended our prostate clinic and were due to undergo prostate biopsy either for an abnormal DRE or an elevated PSA. Patients were informed about the study and randomised prior to the biopsy to receive either 10 ml of periprostatic lignocaine or no anaesthesia. Only two staff were employed in performing these biopsies, both adhered to a similar technique to standardise the study. Patients on anticoagulation were excluded. Antibiotic prophylaxis with an oral quinolone was administered 20 min prior to biopsy and continued for 3 days thereafter. All patients were examined in the left lateral decubitus position. A 7 MHz curved array transrectal probe was used to image the prostate with an ultrasound machine.
Using a 22 gauge spinal needle, 5 ml of 1% lignocaine was injected into the periprostatic region on both the leftand right-hand side of the prostate giving a total of 10 ml of anaesthetic prior to the introduction of the ultrasound probe. The syringe was aspirated before injection to ensure that a vascular structure was not entered. The prostate was examined in the longitudinal and the transverse plane with the ultrasound probe prior to sextant biopsy. In taking the biopsies base, middle and apex were identified and left and right biopsies taken at these sites in a sequential fashion, commencing at the base and working towards the apex.
The local anaesthetic was allowed 10 min to take effect. All patients underwent a six-sector biopsy with an automatic spring-loaded device containing an 18 gauge Tru cut needle. Immediately after completion of the biopsy pain scores were recorded. Patients were asked after the event to rate the discomfort of the overall procedure on a visual analogue scale of 1-10 and a 4-point quality of pain index with 0 ¼ no pain, 1 ¼ mild pain, 2 moderate pain, 3 ¼ severe pain. They were asked to rate the discomfort of the overall procedure, not just the biopsy alone. Statistical analysis was performed with commercially available computer software.
Results
We assessed 64 patients, 33 had periprostatic injection of local anesthetic and 31 had a standard biopsy as a control group. Patient demographics are presented in Table 1 . The mean age of both groups was similar. When analysed the groups showed a normal distribution. We compared the group's pain response with a Student's t-test. When comparing the visual analogue scale response there was no statistical difference between the two groups (P ¼ 0.14). The mean response in the lignocaine group was 3.4 and in the control group was 3.7. When comparing the qualitative pain assessment there was a trend but the two groups were not statistically different (P ¼ 0.07). In the lignocaine group, four patients had undergone a previous biopsy and in the control group three had a previous biopsy.
Discussion
The increased awareness of the public about PSA and prostate cancer has led to more widespread PSA testing. Although there is no formal screening programme in the UK, many men who present to their GP with lower urinary tract symptoms are offered a PSA test. Transrectal ultrasound and biopsy is now performed on an increasing basis. In Europe, the introduction of screening as a Healthcare policy is considered premature and they are awaiting the completion of randomised studies to provide conclusive information about the potential risks and benefits of screening to men who wish to be tested. The American Urological Association has recommended that all men over 50 and high-risk groups aged over 40 y should have an annual PSA and DRE carried out. 3 The positive predictive value for PSA with respect to prostate cancer is 25% and 50-60% in the PSA ranges 4-10 and o10 ng/ml, respectively. 4 To confirm the diagnosis patients must undergo a transrectal ultrasound and biopsy.
Takahashi and Ouchi 5 first introduced this prostate imaging technique in 1963, and its value in biopsy guidance was popularised in the 1970s. 6 Although routinely performed as an outpatient procedure it is not without morbidity; Zisman et al 7 suggested that 64% of patients reported preoperative anxiety. Another report claimed that patients suffered from significant discomfort during the test. 8 The tolerance of this procedure has been the subject of assessment and 19% of patients said they would not undergo the procedure again without some form of anaesthesia. Procedure-related pain is an important issue in prostate cancer diagnosis as so many patients will have to undergo a second or third biopsy, their perception of discomfort at the first biopsy can influence whether they are willing to undergo the procedure again; this has been demonstrated as an important determinant in screening programmes. 9 Interestingly, in our study, we found no significant difference between the two groups, and this was surprising considering the enthusiasm of other authors. We did however make an effort to evaluate the discomfort associated with the overall procedure, and not just with the biopsy itself. We felt that this was important as a number of patients commented on the pain associated with the insertion of local anaesthetic. Although this was not quantified separately in our study it is important that it is taken into account as it is an additional procedure, and the majority of patients still find the biopsy only mildly uncomfortable. 10 As far as we can tell, this was not assessed in studies that have shown a difference between the two groups.
Anatomy
The sensory supply to the prostate is poorly understood. Afferent neurons from the prostate travel through the pelvic plexus to the pelvic and thoracolumbar spinal centres. 11 McNeal has described prostate anatomy on the basis of pathology and embryology. The majority of cancers arise in the peripheral zone, which embryologically arises from the urogenital sinus, whereas the central zone, vas and seminal vesicles are of Wolffian duct origin. It has not been documented whether the sensory supply of the different zones of the prostate may differ. 12 The other structure, which arises from the urogenital sinus, is the urethra, which gains its sensory supply from the pudendal nerve. It has also been noted that apical biopsies may be more uncomfortable than base or midzone biopsies, which may be related to the increased likelihood of catching urethral fibres at this site. Perhaps a periprostatic nerve block will anaesthetise the 
Efficacy of anaesthesia
Other authors have advocated a technique of administering anaesthesia, whereby the prostate gland is pierced by a needle, and on slowly removing the needle the plane between Denonvilliers fascia and the posterior surface of the prostate is recognised by a change in the resistance to injection; this allows a bathing of the posterior surface of the prostate in local anaesthetic. Unfortunately, we found this technique too uncomfortable for patients and used an alternative technique also described where 5 ml of lignocaine was injected into the lateral aspect of the prostate, the periprostatic region. 13 We believe that in order to fully anaesthetise the prostate, the pelvic plexus would have to be anaesthetised and this is best achieved with a caudal regional block.
Another method that has been advocated is the use of rectal lidocaine gel, which is painless in administration; however, in a prospective randomised placebo controlled study it was shown to have no impact on the tolerance of prostate biopsy, again showing the value of a randomised trial. 14 It certainly could be argued that our local anaesthetic technique could be improved and that it may alter our results; however, on observation it was the injection that was of most discomfort, which cannot be altered whatever the technique used. The authors of early reports were so enthusiastic about the value of local anaesthesia that we expected a large difference between the two groups and calculated that a 35% difference would be at least what we expected for the technique to be considered of value. For this to be achieved at an 80% power with a 95% confidence interval, we would need 23 patients in each group; we feel therefore that our sample is statistically valid. The volume of local anaesthetic required has never been fully evaluated; however, comparing with other studies, 10 ml of 1% lignocaine was a reasonable measure. It is also important that adequate time is allowed for the anaesthetic to be effective and 10 min elapsed between infiltration and the first biopsy.
Relevance of study to biopsy protocols
The technique of prostate biopsy is also changing with a more extensive biopsy protocol being adopted, prolonging the procedure and leading to an increased number of biopsies. However, increasing the number of biopsies does not seem to add to pain and anxiety from the procedure. 15 In this study, all patients underwent a standard six-sector biopsy.
Limitations of the study
With the protocol for biopsy changing constantly in order to accommodate a greater number of biopsies, six-sector biopsy is now rarely utilised limiting the generalisibilty of the study. A separate study should be undertaken to quantify how painful local anaesthetic injection is for the patient. Although our study has been adequately powered, the numbers are small and it is conceivable that there is a benefit, which is present, but smaller than the 35% we expected.
Summary and conclusion
If we consider the overall pain score associated with the procedure of local anaesthetic injection and six-sector biopsy and compare it to six-sector biopsy alone we found no significant difference, and therefore no advantage to the administration of periprostatic lignocaine.
